More than $38 billion was spent in the U.S. on Ozempic and Wegovy (semaglutide) in 2023 — a 100% uptick from 2022 expenditure data, according to research published April 24 in the American Journal of Health-System Pharmacy.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
